ANGIODYNAMICS INC ANGO revenue by segment, product and geography
In its fiscal year ending 2026-05-31, ANGIODYNAMICS INC reported revenue across 2 business segments; the largest, Med Device Segment, was $170M, 53.2% of the filed sum (+2.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Med Device Segment$170M53.2%+2.6% yoy
- Med Tech Segment$150M46.8%+18.4% yoy
Members sum to the consolidated $320M for this period.
- Med Device Segment$170M53.2%+2.6% yoy
- Med Tech Segment$150M46.8%+18.4% yoy
Members sum to the consolidated $320M for this period.
- United States$275M85.9%+9.5% yoy
- Outside the United States$45.3M14.1%+9.0% yoy
Members sum to the consolidated $320M for this period.
- Med Device$41.1M52.5%no prior
- Med Tech$37.3M47.5%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.